Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: For patients with locally advanced esophagogastric cancer, the standard of care in the UK is neoadjuvant chemotherapy (NAC) followed by surgery. Prehabilitation exercise training can improve physiological function and fitness. If such improvements translate to increased immune infiltration of tumors, exercise could be prescribed as an immune adjuvant during NAC and potentially improve clinical outcomes. As such, we aimed to determine whether prehabilitation increased tumor infiltrating lymphocytes (TILs).

Methods: We assessed 22 patients with locally advanced esophageal cancer on a randomized control trial comparing 16 weeks of low-to-moderate intensity twice weekly supervised and thrice weekly home-based exercise (Prehab: n = 11) to no prehabilitation (Control: n = 11). Our primary outcome was to compare tumor-immune responses between Controls and Prehab. We compared formalin-fixed paraffin-embedded tumors by high-resolution multispectral immunohistochemistry (mIHC) and NanoString spatial transcriptomics. Secondarily, we determined relationships between changes in fitness to the exercise training and tumor-immune measures. Specifically, we assessed percentage changes in peak cardiorespiratory fitness as assessed by peak oxygen uptake (V̇O) before NAC (Baseline) and after 8 weeks of NAC (Post-NAC), and changes between Baseline and following 8 weeks of NAC recovery before surgery (Pre-surgery) and correlated changes in fitness with tumor-immune responses. Finally, as an exploratory aim, we assessed clinical outcomes between groups, including survival, therapy tolerance, and tumor regrading.

Results: We observed that Prehab had significantly more CD8+ lymphocytes in their tumors (mean difference (diff.) = 1.79, 95% confidence interval (95%CI): 0.76‒2.82, p < 0.001) and their stroma (mean diff. = 1.59, 95%CI: 0.66‒2.52, p < 0.001) than the Controls. When normalized to total numbers of TILs, Prehab had higher levels of CD56+ natural killer (NK) cells (median diff. = 0.87, 95%CI: 0.25‒2.18), p = 0.0274), consisting primarily of CD56 NK cells (median diff. = 0.48, 95%CI: 0.03‒2.53), p = 0.0464). Evaluation of the presence and localization of tumor-associated tertiary lymphoid structures (TLS) in the esophageal tumors revealed that most TLS were in the peritumoral regions. Prehab had a higher TLS cell density (cells/mm; median diff. = 18,959, 95%CI: 13,518‒22,635), p < 0.001) and more clearly defined germinal centers indicative of mature TLS visually. We observed that Prehab maintained their V̇O during NAC while the Controls' V̇O reduced by 9.0% ± 10.2% (mean ± SD) (Post-NAC: p = 0.018). Pre-surgery, Prehab V̇O was a clinically meaningful 3.27 ± 1.31 mL/kg/min higher than Controls (p = 0.022). Between Baseline and Post-NAC, where the Prehab maintained V̇O better than Controls, there were significant positive associations with percentage changes in V̇O and the frequencies of CD8+ TILs (r = 0.531, p = 0.016), programmed death-ligand 1+ (PDL1+) cells (r = 0.566, p = 0.009), and granzyme B+ (GrzB+) TILs (r = 0.582, p = 0.007). Similar relationships were observed for changes in V̇O from Baseline to Pre-Surgery only in the Prehab group. We observed no differences between groups regarding clinical outcomes such as survival, therapy tolerance, or tumor regrading.

Conclusion: We show that exercise training during NAC, which promotes higher levels of cardiorespiratory fitness than no exercise, is associated with increased frequencies of TILs and maturity of TLS. These data suggest that exercise during NAC enhances the immune system. Future studies are warranted to understand the clinical consequences of this.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jshs.2025.101063DOI Listing

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
8
patients locally
8
locally advanced
8
exercise training
8
clinical outcomes
8
tumor-immune responses
8
changes fitness
8
baseline weeks
8
weeks nac
8
nac
5

Similar Publications

A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.

View Article and Find Full Text PDF

Background: The objective of this study was to evaluate the efficacy, safety, as well as the 3-year survival outcomes of neoadjuvant immunotherapy with chemotherapy (NICT) plus surgery in patients with locally advanced esophageal squamous cell carcinoma (ESCC) in real-world settings.

Methods: We performed a retrospective analysis of patients with locally advanced ESCC who underwent surgery after NICT in our hospital between May 2019 and Mar 2022, with a median follow-up of 37.6 months.

View Article and Find Full Text PDF

The association of pre-neoadjuvant SUVmax and post-neoadjuvant change in SUVmax on FDG-PET with survival after oesophagectomy for cancer.

J Gastrointest Surg

September 2025

Department of Upper Gastrointestinal and Hepatobiliary Surgery, Royal Prince Alfred Hospital, Sydney, Australia; RPA Institute of Academic Surgery, Sydney, Australia; School of Medicine, University of Sydney, Sydney, Australia; Surgical Outcomes Research Centre (SOuRCe), Sydney, Australia.

Background: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is currently widely used in staging and re-staging oesophageal cancer after neoadjuvant therapy. The maximal standardized uptake value (SUVmax) is a reproducible parameter that may predict survival. This study aimed to determine the prognostic significance of SUVmax and the change in SUVmax after neoadjuvant treatment (ΔSUVmax) on overall and disease-free survival.

View Article and Find Full Text PDF

ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.

Cell Rep Med

August 2025

Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address:

The diagnostic accuracy of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) after multimodal treatment remains unclear. In a prospective cohort of 132 patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT) followed by clinical response evaluation and surgery, tumor-informed personalized-panel and fixed-panel ctDNA assays are applied to serial blood samples. Personalized ctDNA assay demonstrates a superior baseline detection rate (99.

View Article and Find Full Text PDF

Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.

ESMO Open

September 2025

Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.

Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.

Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.

View Article and Find Full Text PDF